Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
ATF7IP-JAK2 fusion
Cancer:
B Acute Lymphoblastic Leukemia
Drug:
CHZ868
(
JAK2 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
ASH 2022
Title:
150 Novel Drugs to Target JAK2 Rearrangements in Pediatric Acute Lymphoblastic Leukemia
Published date:
11/03/2022
Excerpt:
Finally, we demonstrated the in vivo efficacy of CHZ868 in PAX5::JAK2, ATF7IP::JAK2 and ZEB2::JAK2 patient-derived- xenografts.
DOI:
https://doi.org/10.1182/blood-2022-169437
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login